UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: CLBS |
| Industry | Biopharmaceuticals |
| Founded | 2006 (2006) |
| Headquarters | New York City, New York, U.S. |
|
Key people
|
David J. Mazzo (CEO) |
| Website | caladrius.com |
Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.
The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc. It is headquartered in New York City, New York.
In 2012 they started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow derived cell therapy enriched for CD34+ cells, for Acute Myocardial Infarction. Initial results included a statistically significant mortality benefit. After the interim results reported in Nov 2014 the company clarified the changes to the study.
The cancer therapies (Melapuldencel-T and ovapuldencel-T) below are an autologous dendritic cell-based immunotherapy using the patients own dendritic cells and samples of their tumour to make dendritic cells aimed at the patients tumour antigens. This should activate T cells to attack the tumour.
| 2016-05-14 | Reiterated Rating | Maxim Group | Hold | |
| 2016-05-06 | Reiterated Rating | Maxim Group | Hold | |
| 2016-04-30 | Upgrade | Rodman & Renshaw | Buy | |
| 2016-04-29 | Upgrade | HC Wainwright | Neutral to Buy | $1.25 |
| 2016-04-19 | Reiterated Rating | Maxim Group | Hold | |
| 2016-01-26 | Reiterated Rating | Aegis | Buy | |
| 2016-01-08 | Reiterated Rating | Aegis | Buy | $2.00 |
| 2016-01-08 | Downgrade | HC Wainwright | Buy to Neutral | |
| 2016-01-07 | Downgrade | Maxim Group | Buy to Hold | |
| 2015-12-28 | Reiterated Rating | Maxim Group | Buy | $12.00 to $4.00 |
| 2015-12-22 | Reiterated Rating | Maxim Group | Buy | $12.00 to $4.00 |
| 2015-09-24 | Reiterated Rating | Maxim Group | Buy | |
| 2015-09-24 | Reiterated Rating | WBB Securities | Buy | $7.00 |
| 2015-08-07 | Downgrade | Benchmark Co. | Buy to Hold | $12.00 to $2.00 |
| 2015-06-25 | Reiterated Rating | Maxim Group | Buy | |
| 2015-05-06 | Lower Price Target | Benchmark Co. | Buy | $22.00 to $12.00 |
| 2015-04-30 | Lower Price Target | Maxim Group | Buy | $15.00 to $12.00 |
| 2015-04-06 | Initiated Coverage | MLV & Co. | Buy | $14.00 |
| 2015-01-09 | Initiated Coverage | Oppenheimer | Outperform | $10.00 |
| 2015-01-09 | Initiated Coverage | Oppenheimer Holdings Inc. | Outperform | $10.00 |
| 2015-01-06 | Reiterated Rating | Aegis | Positive | $21.00 |
| 2014-11-24 | Reiterated Rating | Aegis | Buy | |
| 2014-11-18 | Lower Price Target | MLV & Co. | Buy | $17.00 to $14.00 |
| 2014-11-14 | Initiated Coverage | Maxim Group | Buy | $15.00 |
| 2014-09-18 | Reiterated Rating | WBB Securities | Strong-Buy | $27.00 |
| 2014-05-28 | Initiated Coverage | Benchmark Co. | Buy | $22.00 |
| 2014-05-12 | Lower Price Target | Aegis | Buy | $23.00 to $21.00 |
| 2014-01-02 | Boost Price Target | Aegis | Buy | $21.00 to $23.00 |
| 2016-05-14 | Reiterated Rating | Maxim Group | Hold | |
| 2016-05-06 | Reiterated Rating | Maxim Group | Hold | |
| 2016-04-30 | Upgrade | Rodman & Renshaw | Buy | |
| 2016-04-29 | Upgrade | HC Wainwright | Neutral to Buy | $1.25 |
| 2016-04-19 | Reiterated Rating | Maxim Group | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CLBS 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM